ACM
ACIU icon

ACT Capital Management’s AC Immune ACIU Stock Holding History

ACT Capital Management’s Portfolio ACIU Stock Details ACIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-21,500
Closed -$144K – 94
2021
Q3 		$144K Buy
+21,500
New +$154K 0.07% 86

Other funds holding ACIU

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

ACT Capital Management's ACIU Position: Q4 2021 in Review

ACT Capital Management sold out of AC Immune (ACIU) in Q4 2021, closing a stake of 21,500 shares — an estimated $144K sold.

ACT Capital Management first reported a position in ACIU in Q3 2021 and held it in 1 quarter. The position peaked at $144K in Q3 2021. 44 funds tracked by Wall St. Rank hold ACIU as of Q4 2021.

  • ACT Capital Management reported no remaining AC Immune position as of Q4 2021 after selling out during the quarter.
  • ACT Capital Management sold 21,500 AC Immune shares in Q4 2021, an estimated $144K.
  • ACT Capital Management first reported a position in AC Immune in Q3 2021 and held it in 1 quarter.
  • ACT Capital Management's AC Immune position peaked at $144K in Q3 2021.
  • 44 funds tracked by Wall St. Rank held AC Immune as of Q4 2021.

Based on ACT Capital Management's 13F filing for Q4 2021, filed 3 Feb 2022.